DERM vs. CUE, TPST, BTAI, ONCY, ASRT, CMRX, ETON, ASMB, CARM, and MIST
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Cue Biopharma (CUE), Tempest Therapeutics (TPST), BioXcel Therapeutics (BTAI), Oncolytics Biotech (ONCY), Assertio (ASRT), Chimerix (CMRX), Eton Pharmaceuticals (ETON), Assembly Biosciences (ASMB), Carisma Therapeutics (CARM), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
Journey Medical (NASDAQ:DERM) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
Cue Biopharma received 142 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Journey Medical presently has a consensus price target of $8.50, indicating a potential upside of 120.21%. Cue Biopharma has a consensus price target of $8.00, indicating a potential upside of 390.80%. Given Cue Biopharma's higher probable upside, analysts plainly believe Cue Biopharma is more favorable than Journey Medical.
Journey Medical has a net margin of -4.87% compared to Cue Biopharma's net margin of -924.10%. Journey Medical's return on equity of -34.08% beat Cue Biopharma's return on equity.
7.3% of Journey Medical shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 19.4% of Journey Medical shares are held by insiders. Comparatively, 10.2% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Journey Medical has higher revenue and earnings than Cue Biopharma. Journey Medical is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Journey Medical has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.
In the previous week, Journey Medical had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Journey Medical and 0 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.25 beat Journey Medical's score of 0.19 indicating that Cue Biopharma is being referred to more favorably in the news media.
Summary
Journey Medical beats Cue Biopharma on 9 of the 17 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
